Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26266001 | 0.94 | LIPE (0.42) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL32660190 | 0.88 | LIPE (0.42) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL1857739 | 0.84 | LIPE (0.46) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL1576452 | 0.83 | CTSK (0.40) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL477283 | 0.83 | LIPE (0.42) | LIPEL3MBTL1CTSKCA1CA2 | |
| SCHEMBL694641 | 0.81 | LIPE (0.44) | LIPEL3MBTL1CTSKCA1CA2 | |
| SCHEMBL7365934 | 0.81 | LIPE (0.44) | LIPEL3MBTL1CTSKCA1CA2 | |
| SCHEMBL25935482 | 0.76 | LIPE (0.40) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL7449407 | 0.75 | KDM4E (0.42) | LIPEL3MBTL1NFKB1NFKB2RELA | |
| SCHEMBL5651312 | 0.74 | HTT (0.38) | LIPENFKB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | LIPE 3616/4885L3MBTL1 3171/4885NFKB1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.